Table 1.

Select ongoing clinical trials for epidermal growth factor receptor tyrosine kinase inhibitors in the neoadjuvant setting

Study title	Conditions	Interventions	ClinicalTrials.gov identifier
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations	Stage II NSCLC, Stage IIIA NSCLC	Erlotinib	NCT01470716
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage IIIA-N2 Non-small Cell Lung Cancer	EGFR-positive Non-Small Cell Lung Cancer	Icotinib	NCT03749213
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery	Stage I NSCLC Stage IA NSCLC, Stage IB NSCLC, Stage II NSCLC Stage IIA NSCLC Stage IIB NSCLC Stage IIIA NSCLC	Osimertinib	NCT03433469
Neoadjuvant Afatinib Therapy for Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma	Resectable EGFR positive stage III NSCLC	Afatinib	NCT04201756
Neoadjuvant Gefitinib followed by Surgery and Gefitinib In Unresectable Stage III NSCLC With EGFR Mutations (NEGOTIATE)	Unresectable EGFR positive stage III NSCLC	Gefitinib	NCT02347839

NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor